Arabin pessary to prevent adverse perinatal outcomes in twin pregnancies with a short cervix: a multicenter randomized controlled trial (PESSARONE).


Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
08 2022
Historique:
received: 03 10 2021
revised: 17 01 2022
accepted: 28 01 2022
pubmed: 7 2 2022
medline: 27 7 2022
entrez: 6 2 2022
Statut: ppublish

Résumé

The number of twin pregnancies continues to increase worldwide as both the number of pregnancies obtained by medically assisted reproduction and age at first pregnancy keep rising. Preterm delivery is the major complication associated with twin pregnancies. The effectiveness of preventive treatments such as progesterone or cervical cerclage for women with a short cervix is doubtful in twin pregnancies. The effectivity of cervical pessaries in preventing preterm birth and its associated morbidity and mortality is also controversial. We sought to investigate if the Arabin pessary reduces adverse neonatal outcomes in twin pregnancies with a short cervix. This open-label, multicenter, randomized controlled trial on twin pregnancies with a cervical length of <35 mm compared pessary placement at 16+0 to 24+0 weeks' gestation with standard care alone. The primary endpoint was a composite of adverse neonatal outcomes, namely peripartum or neonatal death or significant neonatal morbidity before hospital discharge, defined as at least 1 of the following complications: bronchopulmonary dysplasia, intraventricular hemorrhage grade III to IV, periventricular leukomalacia, necrotizing enterocolitis grade II or higher, culture-proven sepsis, and retinopathy requiring treatment. A sample size of 308 pregnancies was planned to ensure 80% power to compare the proportions of women with at least 1 infant with an adverse neonatal outcome. The intention-to-treat analysis after multiple imputation of missing data, was supplemented with a secondary analysis that controlled for gestational age and cervical length, both at inclusion. The primary endpoint was also compared between randomization groups in the per-protocol population, which excluded patients with prespecified major protocol violations (mostly cervical cerclage and/or progesterone after inclusion). Secondary endpoints included preterm birth, spontaneous preterm birth, and pessary side effects. In total, 315 women were randomized to either receive a pessary (n=157) or standard management (n=158). Overall, 10.8% (34 women) of participants had a missing value for the primary endpoint, mostly (79%) because of the lack of paternal consent for neonatal data collection. In the intention-to-treat analysis, the adverse neonatal outcome occurred in 16.8% of the pessary group vs in 22.5% of the control group (risk ratio, 0.69; 95% confidence interval, 0.39-1.23; P=.210). The per-protocol analysis did not show any significant difference between groups (risk ratio, 0.78; 95% confidence interval, 0.47-1.28; P=.320). The occurrence of preterm birth or spontaneous preterm birth did not differ significantly between groups. No serious side effects were associated with pessary use. Pessary use in our study did not significantly reduce adverse neonatal outcomes in twin pregnancies with a short cervix.

Sections du résumé

BACKGROUND
The number of twin pregnancies continues to increase worldwide as both the number of pregnancies obtained by medically assisted reproduction and age at first pregnancy keep rising. Preterm delivery is the major complication associated with twin pregnancies. The effectiveness of preventive treatments such as progesterone or cervical cerclage for women with a short cervix is doubtful in twin pregnancies. The effectivity of cervical pessaries in preventing preterm birth and its associated morbidity and mortality is also controversial.
OBJECTIVE
We sought to investigate if the Arabin pessary reduces adverse neonatal outcomes in twin pregnancies with a short cervix.
STUDY DESIGN
This open-label, multicenter, randomized controlled trial on twin pregnancies with a cervical length of <35 mm compared pessary placement at 16+0 to 24+0 weeks' gestation with standard care alone. The primary endpoint was a composite of adverse neonatal outcomes, namely peripartum or neonatal death or significant neonatal morbidity before hospital discharge, defined as at least 1 of the following complications: bronchopulmonary dysplasia, intraventricular hemorrhage grade III to IV, periventricular leukomalacia, necrotizing enterocolitis grade II or higher, culture-proven sepsis, and retinopathy requiring treatment. A sample size of 308 pregnancies was planned to ensure 80% power to compare the proportions of women with at least 1 infant with an adverse neonatal outcome. The intention-to-treat analysis after multiple imputation of missing data, was supplemented with a secondary analysis that controlled for gestational age and cervical length, both at inclusion. The primary endpoint was also compared between randomization groups in the per-protocol population, which excluded patients with prespecified major protocol violations (mostly cervical cerclage and/or progesterone after inclusion). Secondary endpoints included preterm birth, spontaneous preterm birth, and pessary side effects.
RESULTS
In total, 315 women were randomized to either receive a pessary (n=157) or standard management (n=158). Overall, 10.8% (34 women) of participants had a missing value for the primary endpoint, mostly (79%) because of the lack of paternal consent for neonatal data collection. In the intention-to-treat analysis, the adverse neonatal outcome occurred in 16.8% of the pessary group vs in 22.5% of the control group (risk ratio, 0.69; 95% confidence interval, 0.39-1.23; P=.210). The per-protocol analysis did not show any significant difference between groups (risk ratio, 0.78; 95% confidence interval, 0.47-1.28; P=.320). The occurrence of preterm birth or spontaneous preterm birth did not differ significantly between groups. No serious side effects were associated with pessary use.
CONCLUSION
Pessary use in our study did not significantly reduce adverse neonatal outcomes in twin pregnancies with a short cervix.

Identifiants

pubmed: 35123930
pii: S0002-9378(22)00098-9
doi: 10.1016/j.ajog.2022.01.038
pii:
doi:

Substances chimiques

Progesterone 4G7DS2Q64Y

Banques de données

ClinicalTrials.gov
['NCT02205541']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

271.e1-271.e13

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Marion Groussolles (M)

Department of Obstetrics and Gynecology, Paule de Viguier Hospital, Toulouse University Hospital, Toulouse, France; Centre for Epidemiology and Research in Population Health, UMR 1295, Study of Perinatal, Pediatric and Adolescent Health: Epidemiological Research and Evaluation Team, Toulouse III University, Toulouse, France.

Norbert Winer (N)

Department of Obstetrics and Gynecology, University Medical Center of Nantes, Centre d'Investigation Clinique Mere enfant, Nantes, France.

Loïc Sentilhes (L)

Department of Obstetrics and Gynecology, Angers University Hospital, Angers, France.

Florence Biquart (F)

Department of Obstetrics and Gynecology, Angers University Hospital, Angers, France.

Mona Massoud (M)

Department of Obstetrics and Gynecology, Hospital Femme-Mère-Enfant, University Lyon 1, Lyon, France.

Alexandre J Vivanti (AJ)

Hopital Antoine Beclere, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Sud University, Clamart, France.

Hanane Bouchghoul (H)

Centre for Research in Epidemiology and Population Health, Hopital Bicetre and University of Paris-Saclay, Paris-Sud University, Université de Versailles Saint-Quentin-en-Yvelines, Institut National de la Santé et de la Recherche Médicale, Bicêtre, France.

Patrick Rozenberg (P)

Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital & Versailles St-Quentin University, Research Unit EA 7285, Poissy, France.

Pascale Olivier (P)

Department of Medical Pharmacology, Hospital Center University de Toulouse, Toulouse, France.

Raoul Desbriere (R)

Department of Obstetrics and Gynecology, Saint Joseph Hospital, Marseille, France.

Celine Chauleur (C)

Department of Gynecology and Obstetrics, University Hospital of Saint-Etienne, Saint-Etienne, France.

Franck Perrotin (F)

Department of Obstetrics and Gynecology, Tours University Hospital, Tours, France.

Frederic Coatleven (F)

Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France.

Florent Fuchs (F)

Department of Obstetrics and Gynecology, Montpelier University Hospital, Montpellier, France.

Florence Bretelle (F)

Department of Obstetrics and Gynecology, Marseille Nord Hospital, Assistance Publique - Hôpitaux de Marseille, Marseille, France.

Vassilis Tsatsaris (V)

Port Royal Maternity Unit, Cochin Hospital, AP-HP, Paris, France; DHU Risks in Pregnancy, Paris Descartes University, Paris, France.

Laurent J Salomon (LJ)

Department of Obstetrics and Fetal Medicine, Necker-Enfants Malades Hospital, AP-HP, Paris Descartes University, Paris, France.

Nicolas Sananes (N)

Department of Maternal Fetal Medicine, Strasbourg University Hospital, Strasbourg, France.

Gilles Kayem (G)

Department of Obstetrics and Gynecology, Trousseau Hospital, AP-HP, Paris, France.

Veronique Houflin-Debarge (V)

Department of Obstetrics and Gynecology, Jeanne de Flandre University Hospital, Lille, France.

Thomas Schmitz (T)

Department of Obstetrics and Gynecology, Hôpital Robert Debré, AP-HP, University Paris Diderot, Paris, France.

Guillaume Benoist (G)

Department of Obstetrics and Gynecology, Caen University Hospital, Caen, France.

Catherine Arnaud (C)

Centre for Epidemiology and Research in Population Health, UMR 1295, Study of Perinatal, Pediatric and Adolescent Health: Epidemiological Research and Evaluation Team, Toulouse III University, Toulouse, France; Clinical Epidemiology Unit, Toulouse University Hospital Center, Toulouse, France.

Virginie Ehlinger (V)

Centre for Epidemiology and Research in Population Health, UMR 1295, Study of Perinatal, Pediatric and Adolescent Health: Epidemiological Research and Evaluation Team, Toulouse III University, Toulouse, France.

Christophe Vayssière (C)

Department of Obstetrics and Gynecology, Paule de Viguier Hospital, Toulouse University Hospital, Toulouse, France; Centre for Epidemiology and Research in Population Health, UMR 1295, Study of Perinatal, Pediatric and Adolescent Health: Epidemiological Research and Evaluation Team, Toulouse III University, Toulouse, France. Electronic address: christophe.vayssiere@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH